StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN – Free Report) in a research note released on Saturday morning. The firm issued a sell rating on the biotechnology company’s stock.
Separately, Lake Street Capital decreased their target price on shares of Evogene from $30.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, August 23rd.
Read Our Latest Stock Analysis on Evogene
Evogene Price Performance
Evogene (NASDAQ:EVGN – Get Free Report) last announced its earnings results on Thursday, August 22nd. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.94). Evogene had a negative return on equity of 72.33% and a negative net margin of 210.26%. The firm had revenue of $0.91 million during the quarter.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC acquired a new stake in shares of Evogene Ltd. (NASDAQ:EVGN – Free Report) in the third quarter, according to its most recent disclosure with the SEC. The firm acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors own 10.40% of the company’s stock.
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
Further Reading
- Five stocks we like better than Evogene
- 3 Warren Buffett Stocks to Buy Now
- Palantir Cracks $50, Is There Still Time to Get on Board?
- What is a Bond Market Holiday? How to Invest and Trade
- Insider Buying Signals Upside for These 3 Stocks
- What Investors Need to Know About Upcoming IPOs
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.